Trial Profile
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Hairy cell leukaemia
- Focus Therapeutic Use
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 19 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.
- 19 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.